

5th Annual

Birth Defects Monitoring and Prevention in Georgia — *Partners' Meeting*

CDC Roybal Campus, Building 19 ♦ 1600 Clifton Rd., Atlanta, Georgia ♦ August 23, 2007

8:00	Registration	
8:30	Welcome	Kathleen Toomey, MD, MPH <i>CoCHP/CDC</i>
8:40	Introduction	Edwin Trevathan, MD, MPH <i>NCBDDD/CDC</i>
8:50	Down syndrome and public health	Sonja Rasmussen, MD, MS <i>NCBDDD/CDC</i>
9:10	Trisomy 21: Research progress to identify its cause and effect	Stephanie Sherman, PhD <i>Department of Genetics Emory University School of Medicine</i>
9:40	Prenatal screening and diagnosis	Nora Doyle, MD, MPH, MSc <i>Department of Gynecology and Obstetrics Emory University School of Medicine</i>
10:10-10:30	<i>BREAK</i>	
10:30	Trends in survival and prevalence of Down syndrome	Adolfo Correa, MD, PhD <i>NCBDDD/CDC</i>
11:00	Referral to service: Overview of state services Children's First Children with Special Needs	Daphne Terry, PhD, MPH, MEd Helen Dulock, DNS, RN <i>Georgia Division of Public Health</i>
11:45	The Emory Down Syndrome Center -- Combining Clinical Services, Research, and Education	Jeannie Visootsak, MD <i>Emory Down Syndrome Clinic</i>
12:15-1:15	<i>LUNCH</i>	
1:15	Clinical care of individuals with Down syndrome across the lifespan	Priya Kishnani, MD <i>Division of Medical Genetics Duke University Medical Center</i>
2:15	Medical and non-medical costs associated with Down syndrome	Scott Grosse, PhD <i>NCBDDD/CDC</i>
2:45	Family perspective	Michelle Norweck, LCSW <i>Down Syndrome Association of Atlanta</i>
3:15	Closing remarks	Coleen Boyle, PhD <i>NCBDDD/CDC</i>

CDC, our planners, and our presenters wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of Dr. Kishnani. She wishes to disclose that she has received honoraria in the past from pharmaceutical companies, Pfizer and Novartis. She also has a provisional patent for the use of cholinesterase inhibitors for another indication (not Down syndrome). Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Kishnani's discussion on clinical trials for Down syndrome. She may discuss the use of Donepezil and Rivastigmine (FDA approved medications for other indications).